RBC Capital Maintains Outperform on Revolution Medicines, Raises Price Target to $321

Benzinga · 19h ago
RBC Capital analyst Leonid Timashev maintains Revolution Medicines (NASDAQ:RVMD) with a Outperform and raises the price target from $260 to $321.